NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Marinus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On A ...

If you bought Marinus shares between March 17, 2021 and May 7, 2024, and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888)-508-6832 or, you may visit the firm's website at www.holzerlaw.com/case/marinus-pharmaceuticals/ to learn more. Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation o ...

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Marinus Pharmaceuticals, Inc. (MRNS) Misled Investors Regarding the Viability of its Drug Candidate SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) securities ...

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- WHAT TO DO NEXT: To join the Marinus class action, go to https://rosenlegal.com/submit-form/? case_id=25735 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 5, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the l ...

Here's Why MRNS Could Experience a Turnaround The RSI reading of 9.98 for MRNS is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand. Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal. So, b ...

Marinus Pharmaceuticals (MRNS) has been on a downward spiral lately with significant selling pressure. After declining 7.6% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. How to Determine if a Stock is Oversold Technically, every stock oscillates between being overbought and oversold irrespective of the quality o ...

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.68 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this epilepsy drug developer would post a loss of $0.64 per share when it actually produced a loss of $0.74, delivering a surprise of -15.63%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Marinus Pharmaceu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-36576 MARINUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 20-0198082 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of (Commission File Number) (IRS Employer Identification incorporation) No.) 5 Radnor Corporate Center, Suite 500 19087 100 Matsonford R ...

Start Time: 16:30 End Time: 17:36 March 1, 0000 ET Q4 2023 Earnings Conference Call March 05, 2024, 16:30 PM ET Company Participants Scott Braunstein - CEO and Chairman Christy Shafer - Chief Commercial Officer Joseph Hulihan - Chief Medical Officer Steven Pfanstiel - CFO and COO Sonya Weigle - SVP, IR, Human Resources and Corporate Affairs Conference Call Participants Brian Abrahams - RBC Capital Markets Peyton Bohnsack - TD Cowen Andrew Tsai - Jefferies Charles Duncan - Cantor Fitzgerald Joon Lee - Truist ...